Investigational Drug Details
| Drug ID: | D326 |
| Drug Name: | Selonsertib |
| Synonyms: | GS-4997; Selonsertib |
| Type: | Chemical drug |
| DrugBank ID: | DB14916 |
| DrugBank Description: | Selonsertib is under investigation in clinical trial NCT03053050 (Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis). |
| PubChem ID: | 71245288 |
| CasNo: | 1448428-04-3 |
| Repositioning for NAFLD: | No |
| SMILES: | Cc1c(cc(c(c1)F)C(=O)Nc1nc(ccc1)c1n(C(C)C)cnn1)n1cc(nc1)C1CC1 |
| Structure: |
|
| InChiKey: | YIDDLAAKOYYGJG-UHFFFAOYSA-N |
| Molecular Weight: | 445.502 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | MAP3K5 inhibitor; ASK1 inhibitor |
| Therapeutic Category: | Anti-oxidative stress; Anticancer agent |
| Clinical Trial Progress: | Phase 3 on-going (NCT03053050; NCT03053063: Forty-eight weeks of selonsertib monotherapy had no antifibrotic effect in patients with bridging fibrosis or compensated cirrhosis due to NASH.) |
| Latest Progress: | Failed in clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0130 | NCT02781584 | Phase 2 | Completed | Has Results | June 13, 2016 | March 16, 2022 | Details |
| L0212 | NCT03053050 | Phase 3 | Terminated | Has Results | February 13, 2017 | June 29, 2020 | Details |
| L0213 | NCT03449446 | Phase 2 | Completed | Has Results | March 21, 2018 | December 3, 2020 | Details |
| L0214 | NCT03053063 | Phase 3 | Terminated | Has Results | January 30, 2017 | May 7, 2020 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| S04 | Anti-oxidative stress | oxidative stress | α-tocopherol: antioxidant | Vitamin E | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01245 | 34815444 | Sci Rep | A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates. | Details |
| A01666 | 34662449 | Hepatology | Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. | Details |
| A02701 | 34278169 | Hepatol Commun | Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. | Details |
| A03067 | 34144391 | Redox Biol | Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPARγ binodal complementary modules. | Details |
| A03482 | 33987427 | Ann Transl Med | Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. | Details |
| A04097 | 33761646 | Medicine (Baltimore) | The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. | Details |
| A05080 | 33385317 | J Dig Dis | Efficacy and safety of drugs for nonalcoholic steatohepatitis. | Details |
| A05119 | 33368954 | Diabetes Obes Metab | Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. | Details |
| A05306 | 33307033 | Gastroenterology | The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. | Details |
| A05376 | 33278029 | Pharmacotherapy | Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. | Details |
| A05661 | 33169409 | Hepatology | Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. | Details |
| A06102 | 33007418 | Pharmacol Res | Endoplasmic reticulum stress and protein degradation in chronic liver disease. | Details |
| A06984 | 32673798 | Mol Metab | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. | Details |
| A07905 | 32316235 | J Clin Med | The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis. | Details |
| A08128 | 32237916 | Expert Opin Pharmacother | Current and new pharmacotherapy options for non-alcoholic steatohepatitis. | Details |
| A08327 | 32151660 | Metabolism | Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. | Details |
| A08342 | 32147362 | J Hepatol | Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. | Details |
| A08711 | 32015483 | Sci Rep | Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. | Details |
| A08933 | 31931543 | Z Gastroenterol | [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?] | Details |
| A10083 | 31495973 | Hepatol Res | Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. | Details |